Adaptimmune Therapeutics PLC
ADAPY· OTC
ADAPYAdaptimmune Therapeutics PLC
Filed Aug 3, 2017 · 10-Q · 34 days after period end · 0001104659-17-049218
| Metric | Q2 2017 | Q2 2016 | Q2 2015 |
|---|---|---|---|
| Revenue | $3.52M | $328.00K | $2.78M |
| Net Income | -$20.22M | -$22.10M | -$14.57M |
| EPS Diluted | -$0.04 | -$0.05 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
ended Jun 30, 2017 · filed Aug 3, 2017 · 34 d after period end
